Navigation Links
Neurochem reports results for fourth quarter and fiscal year 2007 and important advances on corporate objectives
Date:2/20/2008

aled $1,397,000 for the current quarter ($10,581,000 for the year), compared to $2,819,000 for the same quarter in the previous year ($11,522,000 for the year). These costs are incurred to support the overall activities of the Company. The decrease is mainly attributable to a reduction in management bonuses, and in performance-based fees due to Picchio International Inc.

Arbitral award amounted to nil for the current quarter and year compared to nil for the quarter ended December 31, 2006 and $1,835,000 for the year ended December 31, 2006. This expense related to the dispute with Immtech Pharmaceuticals, Inc. (formerly known as Immtech International, Inc. (Immtech), which came to a conclusion in January 2007 when Immtech, the University of North Carolina at Chapel Hill (UNC), and Georgia State University Research Foundation, Inc. filed with the Federal District Court for the Southern District of New York, U.S.A. a Notice of Voluntary Dismissal. The plaintiffs voluntarily dismissed their complaint against Neurochem in the Federal District Court without any payment, license, business agreement, concession or compromise by Neurochem.

Reimbursable costs amounted to $64,000 for the current quarter ($396,000 for the year), compared to $178,000 for the same period in the previous year ($712,000 for the year), and consist of costs incurred on behalf of Centocor in respect of eprodisate (KIACTA(TM))-related activities and reimbursable by Centocor.

Stock-based compensation amounted to $1,421,000 for the current quarter ($4,275,000 for the year), compared to $924,000 for the corresponding quarter in the previous year ($3,569,000 for the year). This expense relates to stock options and stock-based incentives, whereby compensation cost in relation to stock options is measured at fair value at the date of grant and is expensed over the award's vesting period. The increase is due to new stock options granted during the past year.

Depreciation, amortiza
'/>"/>

SOURCE NEUROCHEM INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related medicine news :

1. Neurochem to present at 2008 BIO CEO & Investor Conference - Presentation will be Web cast live
2. Neurochem appoints Mr. Gary Schmid as CEO of new nutraceutical business
3. Neurochem to present at JPMorgan Healthcare Conference
4. Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
5. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
6. Neurochem announces departure of Dr. Philippe Calais, President, Global Business
7. Neurochem reports results for third quarter of fiscal 2007
8. Emageon Reports Fourth Quarter and 2007 Financial Results
9. Cyberonics Reports Operating Profit for Third Quarter FY08 and Announces Share Repurchase Program
10. Platinum Underwriters Holdings, Ltd. Reports Record Fourth Quarter and Year Ended December 31, 2007 Financial Results
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... a very familiar "lub-dub" pattern that speeds up or ... pattern itself isn,t as regular as you might think. ... vary even at a "constant" heart rateand that variability, ... Reduced heart rate variability (HRV) has been found to ... congestive heart failure and inflammation. For athletes, a drop ...
(Date:9/22/2014)... 22, 2014 WHO: LiveOps, Inc., ... customer service solutions. , WHAT: The 10th annual ... customer care for the connected consumer. Constant change ... offer new challenges and opportunities for customer experience ... identify best practices, network and learn from fellow ...
(Date:9/22/2014)... By Tara Haelle ... (HealthDay News) -- Measuring how quickly a child,s brain ... according to a new study. Observing children,s ... is currently possible, the study authors reported. "The ... information is associated with autism severity is hugely promising," ...
(Date:9/22/2014)... CA (PRWEB) September 22, 2014 ... California for a three-day conference to discuss brain-related ... brain injury from concussions and neurodegenerative disorders. ... medical director affiliated with a Silverado memory care ... of dedicated expertise in memory care, hosts the ...
(Date:9/22/2014)... September 22, 2014 The report ... application, end user, and geography. The equipment segment ... physiotherapy equipment market, by product. However, the accessories ... CAGR in the forecast period, owing to the ... Electric stimulation and ultrasound segments are the fastest-growing ...
Breaking Medicine News(10 mins):Health News:Variability keeps the body in balance 2Health News:Variability keeps the body in balance 3Health News:Variability keeps the body in balance 4Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:6.8% CAGR for Physiotherapy Equipment Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 5
... offers a low cost, non-invasive alternative to conventional ... having coronary artery disease; true even if the ... a study performed at the Thomas Jefferson University ... patients who had one or more calcified coronary ...
... shown that babies exposed to tobacco in utero are ... are at increased risk for sudden infant death syndrome. ... these babies are also less likely to self-soothe and ... did not smoke during pregnancy. , Researchers from The ...
... the leading,provider of internet and digital information accessibility ... award-winning System Access,software. With this release, Serotek ... support for 64-bit operating systems. This is ... IT professionals,alike. , ...
... ROME, N.Y., Dec. 1 To help prevent the spread ... is using two new,products that kill germs on hands and ... According to Infection Prevention Director LeAnna Grace, the hospital,conducted a ... sanitizing lotion to evaluate how well they work and was ...
... is a statement from Jeff Levi, Ph.D., Executive Director of ... and Drug Administration,s (FDA) progress report on the Food Protection ... lacks a real plan for food protection. The staff ... some key initiatives to improve food safety, but they can ...
... Pressure BioSciences, Inc. (Nasdaq: PBIO ) ("PBI" or ... significantly reduce costs, centralize core operations, and refocus the Company,s ... found significant market acceptance. The restructuring program includes: , ... personnel of eight full-time employees (40% of the workforce) , ...
Cached Medicine News:Health News:Newborns exposed to maternal smoking more irritable, difficult to soothe 2Health News:Serotek First to Offer 64-Bit Support 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 2Health News:MRSA and C. difficile Infections Reduced by 50% in Hospital Study 3Health News:TFAH Statement: FDA Food Protection Plan is Insufficient 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 2Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 3Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 4Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 5Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 6Health News:Pressure BioSciences, Inc. Announces Restructuring, Significant Cost Reduction Initiatives, and Sharpened Focus 7
(Date:9/22/2014)... , Sept. 22, 2014  Neuralstem, Inc. (NYSE MKT: ... site investigator at Emory University, presented long-term follow up ... neural stem cells in the treatment of amyotrophic lateral ... presentation, which occurred at the Annual Symposium on ALS ... , on Friday, and was not open to ...
(Date:9/22/2014)... , Sept. 22, 2014  Olympus, a global ... for medical and surgical procedures, among other core ... with Munich -based Brainlab to ... Navigation. This agreement applies to the US ... U.S. sales and all distribution outside the U.S. ...
(Date:9/22/2014)... 22, 2014  Inovio Pharmaceuticals, Inc. (NASDAQ: ... a phase I clinical trial in patients with ... tolerability, and immunogenicity of INO-3106. This immunotherapy targets ... aerodigestive cancers. Aerodigestive cancers affect the ... parts of the esophagus and windpipe. The unmet ...
Breaking Medicine Technology:Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 2Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 3Neuralstem ALS Investigator Presents Long-Term Follow Up Phase I Data 4Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 2Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 3Olympus Partners with Brainlab as Exclusive Distributor for ENT Products in U.S. Market 4Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 2Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 3Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers 4
... FOREST, Ill., Sept. 6, 2011 Hospira, Inc. ... in generic injectable pharmaceuticals, today announced positive results from ... erythropoietin (EPO) in patients with renal (kidney) dysfunction who ... equal pharmacokinetics, or blood level and distribution in the ...
... 2011 Johnson & Johnson (NYSE: JNJ ) ... Tuesday, September 13 th , at the Grand Hyatt New ... New York, NY.  Dominic Caruso, Vice President, Finance and Chief ... the company in a session scheduled at 10:20 a.m. (Eastern). ...
Cached Medicine Technology:Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 2Hospira Announces Positive Results From Phase I U.S. Clinical Trial of Biosimilar Erythropoietin in Renal Patients 3
... Western Blot Kits provide a sensitive and ... Borrelia burgdorferi. Proteins from the spirochete are ... antigens are fractionated according to molecular weight ... in the presence of sodium dodecyl sulfate. ...
Surgitie&trade Single Use Ligating Loops with Delivery System...
Surgitie&trade Single Use Ligating Loops with Delivery System...
ENDO STITCH™ Single Use Loading Units....
Medicine Products: